These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25709442)

  • 1. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
    Wu H; Infante JR; Keedy VL; Jones SF; Chan E; Bendell JC; Lee W; Kirschbrown WP; Zamboni BA; Ikeda S; Kodaira H; Rothenberg ML; Burris HA; Zamboni WC
    Int J Nanomedicine; 2015; 10():1201-9. PubMed ID: 25709442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.
    Wu H; Infante JR; Keedy VL; Jones SF; Chan E; Bendell JC; Lee W; Zamboni BA; Ikeda S; Kodaira H; Rothenberg ML; Burris HA; Zamboni WC
    Eur J Clin Pharmacol; 2013 Dec; 69(12):2073-81. PubMed ID: 23989300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.
    Infante JR; Keedy VL; Jones SF; Zamboni WC; Chan E; Bendell JC; Lee W; Wu H; Ikeda S; Kodaira H; Rothenberg ML; Burris HA
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):699-705. PubMed ID: 22941375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
    Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
    Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
    Rivory LP; Haaz MC; Canal P; Lokiec F; Armand JP; Robert J
    Clin Cancer Res; 1997 Aug; 3(8):1261-6. PubMed ID: 9815808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.
    Sasaki Y; Hakusui H; Mizuno S; Morita M; Miya T; Eguchi K; Shinkai T; Tamura T; Ohe Y; Saijo N
    Jpn J Cancer Res; 1995 Jan; 86(1):101-10. PubMed ID: 7737901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
    Drengler RL; Kuhn JG; Schaaf LJ; Rodriguez GI; Villalona-Calero MA; Hammond LA; Stephenson JA; Hodges S; Kraynak MA; Staton BA; Elfring GL; Locker PK; Miller LL; Von Hoff DD; Rothenberg ML
    J Clin Oncol; 1999 Feb; 17(2):685-96. PubMed ID: 10080615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
    Canal P; Gay C; Dezeuze A; Douillard JY; Bugat R; Brunet R; Adenis A; Herait P; Lokiec F; Mathieu-Boue A
    J Clin Oncol; 1996 Oct; 14(10):2688-95. PubMed ID: 8874328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
    Thompson PA; Gupta M; Rosner GL; Yu A; Barrett J; Bomgaars L; Bernstein ML; Blaney SM; Mondick J
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-37. PubMed ID: 18278496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
    Zamboni WC; Strychor S; Maruca L; Ramalingam S; Zamboni BA; Wu H; Friedland DM; Edwards RP; Stoller RG; Belani CP; Ramanathan RK
    Clin Pharmacol Ther; 2009 Nov; 86(5):519-26. PubMed ID: 19675541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors.
    Kimura T; Kashiwase S; Makimoto A; Kumagai M; Taga T; Ishida Y; Ida K; Nagatoshi Y; Mugishima H; Kaneko M; Barrett JS
    Int J Clin Pharmacol Ther; 2010 May; 48(5):327-34. PubMed ID: 20420789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
    Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
    Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.
    Konishi H; Takagi A; Kurita A; Kaneda N; Matsuzaki T
    BMC Cancer; 2012 Oct; 12():462. PubMed ID: 23046546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.
    Miya T; Goya T; Fujii H; Ohtsu T; Itoh K; Igarashi T; Minami H; Sasaki Y
    Invest New Drugs; 2001; 19(1):61-7. PubMed ID: 11291833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
    Sasaki Y; Yoshida Y; Sudoh K; Hakusui H; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K
    Jpn J Cancer Res; 1995 Jan; 86(1):111-6. PubMed ID: 7737902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
    van Erp NP; Baker SD; Zhao M; Rudek MA; Guchelaar HJ; Nortier JW; Sparreboom A; Gelderblom H
    Clin Cancer Res; 2005 Nov; 11(21):7800-6. PubMed ID: 16278402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.